Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/24/2025

Management of Familial Hypercholesterolemia

Initial Treatment Strategy for Adults

  • The American College of Cardiology recommends initiating high-intensity statin therapy immediately upon diagnosis of familial hypercholesterolemia, with a goal of achieving ≥50% LDL-C reduction from baseline, adding ezetimibe if LDL-C remains >100 mg/dL despite maximal tolerated statin therapy, and escalating to PCSK9 inhibitors if goals are not met with combination therapy 1, 2, 3
  • High-intensity statin therapy, such as atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily, should be initiated immediately upon diagnosis, with the primary goal of achieving ≥50% reduction in LDL-C from baseline 2, 3
  • For patients with severe hypercholesterolemia, starting at 40 mg atorvastatin daily is reasonable, and baseline liver function tests, creatine kinase, glucose, and creatinine should be obtained before initiating therapy 2, 3

Escalation Algorithm When Goals Not Met

  • Ezetimibe 10 mg daily should be added if LDL-C remains >100 mg/dL after 4-6 weeks on maximal tolerated statin, as it provides an additional 15-25% LDL-C reduction and has demonstrated cardiovascular risk reduction in patients with acute coronary syndrome 2
  • Colesevelam 3.75 g daily can provide an additional 18.5% LDL-C reduction when added to statin plus ezetimibe, but its use is limited by gastrointestinal side effects and drug interactions 2
  • PCSK9 inhibitor therapy should be added if LDL-C remains ≥100 mg/dL despite maximal statin plus ezetimibe, as it provides ≥50% additional LDL-C reduction and is well-tolerated 2

Treatment Goals Based on Risk Stratification

  • For patients without additional ASCVD risk factors, the target LDL-C is <135 mg/dL or approximately 50% reduction from baseline, and non-fasting blood samples may be used to monitor LDL-C levels in those receiving stable therapy 5
  • For patients with additional ASCVD risk factors, the target LDL-C is <100 mg/dL, and more aggressive treatment is warranted given the cumulative atherosclerotic burden 5, 3
  • For patients with established ASCVD, the target LDL-C is <70 mg/dL, and combination therapy should be considered as first-line treatment in highest-risk patients 5

Pediatric Patients (Age ≥10 Years) with Heterozygous FH

  • Statin therapy should be initiated at age 10 years or older, starting with atorvastatin 10 mg daily, and consideration should be given to earlier initiation if LDL-C >190 mg/dL on two occasions or if multiple ASCVD risk factors are present 5
  • Treatment goals for pediatric patients include targeting LDL-C <135 mg/dL or approximately 50% reduction if no additional risk factors, and <100 mg/dL if additional ASCVD risk factors are present 5

Homozygous FH Management

  • Aggressive multi-drug therapy should be initiated immediately upon diagnosis, ideally by age 2 years, with a high-potency statin and rapid up-titration to maximally tolerated doses, and addition of ezetimibe and colesevelam as needed 5
  • PCSK9 inhibitor therapy should be added within 8 weeks in patients without biallelic LDLR null mutations, and lipoprotein apheresis should be initiated if pharmacotherapy is inadequate 5
  • Treatment goals for homozygous FH include targeting LDL-C <100 mg/dL in the absence of ASCVD or major risk factors, <70 mg/dL with imaging evidence of ASCVD or additional major risk factors, and <55 mg/dL with previous ASCVD event 5

Monitoring Strategy

  • Lipid panel should be assessed 4-6 weeks after initiating or adjusting therapy, and liver enzymes should be monitored periodically while on statin therapy 3
  • Creatine kinase should be checked if muscle symptoms develop, and lipid panel should be reassessed every 6-12 weeks until goals are achieved 3, 4

Critical Pitfalls to Avoid

  • Delaying pharmacotherapy in favor of lifestyle modifications alone is not recommended, as FH patients have lifetime exposure to elevated LDL-C from birth, making early aggressive treatment essential 2, 3
  • Bile acid sequestrants should not be used when triglycerides >200 mg/dL, and caution should be exercised when combining fibrates with statins due to increased myositis risk 4
  • Patients should be instructed to report muscle symptoms immediately, and family screening should be performed to identify other affected individuals 3
  • Elevated lipoprotein(a) should be addressed as an independent risk factor, with more aggressive LDL-C lowering targets warranted if lipoprotein(a) >300 mg/dL 3